Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Exploring Emphysema Disease Market Growth with DLI's Drug Insights, Pricing and Market Strategy Analysis, Clinical Trial Assessment, and Regulatory Consulting Services | Disease Landscape Insights

This image opens in the lightbox

News provided by

Disease Landscape Insights

11 Oct, 2023, 14:15 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, Oct. 11, 2023 /PRNewswire/ -- Emphysema Disease is a lung disease affecting a large number of individuals worldwide. It is known to predominantly affect people with a history of smoking or harmful irritant exposure. According to an epidemiology study conducted by the American Lung Association, more than one million people are living with this condition in the US alone. It is advisable for patients to consult an emphysema specialist when they experience any symptoms.

Emphysema is a chronic ailment which causes severe damage in the walls of the alveoli. The air sacs located in the lungs that are responsible for exchanging oxygen and CO2 during the breathing process is known as alveoli. In this condition, the alveoli lose their elasticity which in turn impacts their capacity of expanding and contracting properly. It is worth noting that emphysema is considered one of the two main components of chronic obstructive pulmonary disease (COPD).

Disease Landscape Insights has been playing a significant role in educating the Emphysema Disease Market players about this ailment. From providing comprehensive disease overview to assisting them in the drug development endeavours, DLI's healthcare consulting services are indeed commendable. Further, it has been helping the industry participants with treatment gaps identification, clinical trial feasibility analysis, commercial strategy analysis, product pipeline analysis, and product portfolio extension, among others.  Apart from that it also offers comprehensive pharma consulting services, new product launch services, and post launch services while aiding the formulation of drug launch strategies, pricing and reimbursement ideas, along with disease burden management strategies.

Price and Market Access

Causes and Symptoms:

The major causes behind chronic respiratory illnesses including COPD and Emphysema are excessive smoking, long-term exposure to air pollutants, such as vehicle exhaust or industrial fumes, and exposure to second hand smoke. Alongside, people who work in environments with high levels of dust, chemicals, or fumes, such as construction workers or miners are highly vulnerable to this ailment.

Notably, a genetic deficiency of a protein called alpha-1 antitrypsin can also increase the risk of emphysema in individuals.

This disease progresses gradually over the years and most of the time its symptoms go unnoticed until significant lung damage has been done. Some of the common symptoms of this ailment that should not be ignored are chronic cough, shortness of breath, chest tightness, wheezing, fatigue, weight loss, and increased mucus production. Emphysema Stages are characterized by following the staging system known as Global Initiative for Chronic Obstructive Lung Disease (GOLD) staging system. According to this, emphysema is bifurcated into four stages namely, mild, moderate, severe, and very severe.

Discover More About Pricing and Reimbursement, Epidemiology Study, and Healthcare @

https://www.diseaselandscape.com/downloadsample/postid/32

Emphysema diagnosis if done at its early stage reduces the risk of severe complications. It is easy for medical professionals to strategize a prompt treatment plan when it is diagnosed at the mild stag. Various treatment therapeutics like emphysema medications and therapies have been developed that can not only alleviate the symptoms but also cure the disease before any serious damage is done to the lungs.

Role of Clinical Trials:

Clinical trials are carefully designed and controlled research studies conducted to evaluate the safety and effectiveness of medical treatments, drugs, or interventions in human participants. Various pharmaceuticals and medical research organizations are developing treatment entities for emphysema. Their potential drugs and therapies are undergoing clinical trial phases which can be quite complexed in nature. DLI has been playing a vital role in the overall clinical trial management by expediting the entire process. It has deep dive expertise in optimizing trial designs, patient recruitment strategies, and data analysis, ultimately contributing to more effective and efficient clinical trials for the development of novel treatments and therapies for emphysema.

Unlock the Benefits Today! Get Started Now and Elevate Your Experience @

https://www.diseaselandscape.com/checkout?report_id=32

Final Words:

Emphysema is a type of COPD that predominantly affects the air sacs of the lungs known as alveoli. It is mainly triggered by excessive smoking, exposure to irritants and toxins, and genetic issues, among others. Many patients do not experience any symptoms until significant damage has been done to  the  lungs. That is why regular screening and routine checkup is must especially for the ones who have a history of smoking and those who are exposed to occupational hazards. DLI has been helping players in solidifying their position in this vertical by supporting them in their research work, drug development, launch, and market access endeavours, among others. This health consultant has joined hands with the industry participants in their mission to transform the lives of emphysema patients.

Browse Through More Environmental Diseases Research Reports.

Related Report:

Posluma: A Targeted Oncology Cutting-Edge Advancement in Prostate Cancer Imaging.

Fezolinetant by Veozah: Advancing Women's Health by Astellas Pharma Inc.

A Glimmer of Hope for Migraine Sufferers: Zavzpret.

Rethinking Treatment Options for a Better Future with Hemophilia Gene Therapy.

Reach New Heights with Mass Production of Benzathine Penicillin G as We Overcome the Challenge.

 Case study on the development of novel medications.

Case Study: Software Application for Personalized Care with Data-Driven Insights.

Case Study: Cancer Vaccine Targeting an Antigen.

Case Study: Lung Cancer Immunotherapy Combination Trials.

software implementation for inventory and supply chain management.

Asset scouting for cystic fibrosis.

The Successful Commercialization of a Revolutionary Non-Invasive Glucose Monitoring Device after Regulatory Approval.

Investing in pancreatic cancer chemotherapy drugs.

Solid Tumor Diseases: A Comprehensive Guide to Detection and Therapeutic Strategies

Demodex Blepharitis: Diagnosis, Treatment, and Prevention

Duchenne Muscular Dystrophy (DMD): A Comprehensive Guide for Patients and Families

Hemophilia Disease Explained: Causes, Symptoms, and Treatment Options

Spinal Muscular Atrophy (SMA) Disease Chronicles: Navigating Life with Spinal Muscular Atrophy

Predictive analytics powered by AI: Unlocking Insights for the Future of Healthcare.

Natural Language Processing (NLP) in Healthcare: Unlocking the Potential.

About Disease Landscape:  

Disease Landscape, a pioneering company specializing in Disease Intelligence, Pricing, and Market Access. Utilizing the power of data analytics, Disease Landscape Insights is dedicated to the healthcare sector with invaluable, finely crafted insights and recommendations regarding global pricing and market access strategies. As a specialized firm, we are committed to delivering unparalleled insights into pricing and market access, custom-tailored to the healthcare and pharmaceutical industries. Our data-driven solutions and cutting-edge technology position us as your trustworthy partner, offering swift, adaptable, and evidence-based alternatives to traditional market access and pricing research methods.  

Our core competencies encompass Market Research Services, Consulting Services, Global Pricing and Market Access, Epidemiology Studies, as well as Product Portfolio and Pipeline Services. Our expertise lies in furnishing comprehensive data intelligence throughout every phase of drug and device research.  

Contact Us:  
Disease Landscape Insights LLP  
6th Floor, Sr No.207, Office A H 6070 Phase 1  
Solitaire Business Hub, Viman Nagar  
Pune, Maharashtra, 411014.
Sales Contact: +44-2038074155  
Asia Office Contact: +917447409162 
Email: ajay@diseaselandscape.com    
Email: vishal@diseaselandscape.com
Blog: https://www.diseaselandscape.com/blogs
Case Study: https://www.diseaselandscape.com/casestudies    
Pharma consulting Services 
Follow Us: LinkedIn | Twitter | Facebook

Logo: https://mma.prnewswire.com/media/2217060/Disease_Landscape_Insights_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.